Stay Ahead with New Guidance on HPV Testing

The American Society for Colposcopy and Cervical Pathology (ASCCP) has issued new guidelines reflecting the importance of extended genotyping in HPV testing to support an enhanced standard of patient care. BD Onclarity™ HPV Assay is the first FDA-approved HPV assay that individually identifies 6 genotypes to be cited in guidelines for the clinical management of a positive HPV test result.1 The new guidelines represent a significant step forward in cervical cancer prevention and management. They offer a more precise and effective approach to screening for HPV, which in turn improves treatment design and supports efforts to eliminate cervical cancer. In addition, a new CPT code has been issued to identify HPV tests that incorporate DNA testing and extended genotyping. BD Onclarity™ is the only test that combines extended genotyping and FDA approval for self-collection in a healthcare setting. This webinar will cover extended genotyping, its importance in providing enhanced patient care and how to code correctly to capture the new reimbursement rate associated with HPV tests that incorporate extended genotyping.

Health economic and reimbursement information provided by BD is gathered by third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. BD encourages providers to submit accurate and appropriate claims for services. It is always the provider’s responsibility to determine medical necessity, the proper site for delivery of any services and to submit appropriate codes, charges and modifiers for services that are rendered. BD recommends that you consult with your payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters. BD does not promote the use of its products outside the FDA-market authorized labels.

Learning Objectives: 

1. Understanding new ASCCP extended genotyping guidelines.

2. Explanation of extended genotyping.

3. Review of the new CPT code for HPV testing.